Business Wire

Actility Selects iBASIS and Sequans to Deploy LTE-M Solutions With eSIM and iSIM

2.3.2023 18:18:00 EET | Business Wire | Press release

Share

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Sequans Communications S.A. (NYSE: SQNS), a leading developer and provider of 5G/4G chips and modules, today announced that Actility, a leading provider of IoT connectivity platform, has chosen iBASIS and Sequans to roll out programmable cellular IoT solutions with eSIM and iSIM.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005808/en/

Actility had previously worked closely with iBASIS to enable roaming between private unlicensed networks powered by ThingPark EPC Connector and public networks, using Simfony’s CMP platform, now fully integrated with iBASIS’ Global Access for Things IoT portfolio. The longstanding partnership between iBASIS and Sequans has produced several successful proofs of concept.

The new ultra-low-power multi-technology trackers of Abeeway, a fully owned Actility subsidiary, will benefit from Sequans Monarch 2 LTE-M/NB-IoT platform with integrated iSIM and the connectivity profile provided by iBASIS, allowing the device to connect to cellular networks worldwide. Actility will also benefit from Sequans Monarch 2 being the first iSIM implementation that has achieved common criteria EAL5+ certification, allowing the use of iBASIS’ intelligent profile selection technology with remote update using multiple Tier-1 operator profiles as provided for eSIM.

iSIM is fully integrated in the cellular modem and microcontroller unit on a single system on chip (SoC). It relies on the existing eSIM infrastructure accessing 2/3/4/5G networks using the global footprint of iBASIS. iSIM is considered to be the future of connectivity technology for many IoT deployments.

An important step forward in the IoT industry, iSIM will positively influence device design in the areas of space optimization, and reduction of energy and power consumption. By eliminating the need for a separate SIM chip, iSIM will provide the customer with a more streamlined supply chain experience when manufacturing a device using cellular connectivity. The entire supply chain will benefit from the reduction of materials which will lead to lower costs for manufacturers.

According to Counterpoint Research, beyond 2027 iSIM is projected to take over as the dominant SIM form factor, with the shipments of iSIM-capable devices poised to scale to 7 billion units between 2021 and 2030. 

With the iBASIS Global Access for Things industry-leading coverage, eSIM/iSIM enables enterprises to easily adopt a single global, remotely programmable SIM that provides mobile data connectivity to smart devices all over the world.

“After recent collaboration with iBASIS, adding iBASIS connectivity on our Monarch 2 module with eSIM, and having fully tested the global connectivity on iSIM, we are now advancing into an integrated production phase driven by a customer need,” said Louis Chuang, EVP of Sequans’ Massive IoT Business Unit. “We are thrilled to reach this important milestone with iBASIS whereby we can offer customers a powerful iSIM capability, along with low power consumption, cost-efficiency, and GNSS support.”

“After being recognized as a leader in the cellular IoT connectivity market with eSIMs, we are delighted to implement iSIM technology together with our trusted partner Sequans,” said Ajay Joseph, CEO IoT & CTO, iBASIS. “After many years of research and development, while deploying iSIM technology in trial environments, it is a great achievement by our teams. This once again underlines that iBASIS is a frontrunner and truly lives by its motto: ‘Be there first’. We strongly believe that iSIM will become a dominant factor within the IoT industry and I am proud to see that we are now able to provide our longstanding customer Actility with our proven IoT connectivity on iSIM.”

“Our focus is ultra-low-power industrial IoT connectivity. The new cellular trackers of our subsidiary Abeeway leverage LTE-M and NB-IoT, and our ThingPark EPC Connector for unlicensed private cellular networks (such as CBRS) rely on recent 3GPP slicing technologies,” said Olivier Hersent, CEO of Actility. “We needed cutting edge partners to support reliable LTE-M connections with PSM/eDRX options in permanent roaming as well as iSIMs: after extensive testing we selected Sequans for their ability to support iSIMs and because 100 percent of their software stack is developed in-house, and iBASIS for their ability to support complex integration and their focus on quality, based on proactive testing. Together, I think we form the dream team for industrial low-power IoT.”

To find out more, visit iBASIS in Hall 2, MR 2A6 and 2A8, and Sequans in Hall 5, Stand 5H40, at Mobile World Congress from February 27 to March 2 in Barcelona.

ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 26 offices worldwide. For more information, please visit iBASIS.com.

ABOUT SEQUANS
Sequans Communications S.A. (NYSE: SQNS) is a leading developer and supplier of cellular IoT connectivity solutions, providing chips and modules for 5G/4G massive and broadband IoT. For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability. For 5G/4G broadband IoT applications, Sequans offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications. Founded in 2003, Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Finland, Taiwan, South Korea, and China. Visit Sequans online at www.sequans.com, and follow us on Twitter and LinkedIn.

ABOUT ACTILITY
Actility is the world leader in Low-Power Wide-Area Networks (LPWAN) industrial-grade connectivity solutions for the Internet of Things. Actility provides its ThingPark platform and network technology to deploy, operate and maintain public and private wireless IoT networks within a unified, scalable and versatile network infrastructure. The vast majority of nationwide LPWAN network service providers and hundreds of enterprises trust ThingPark all over the world. Through its subsidiary Abeeway, Actility also provides patented ultra-low power tracking solutions. ThingPark Market offers the largest selection of interoperable IoT gateways, devices and applications to simplify and accelerate deployment of numerous use cases.  Contact us here: https://www.actility.com/contact 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

iBASIS
Céline Gregoire
EVP, Marketing
+1 617.501.2788
cgregoire@iBASIS.net

ACTILITY
Frank Koopman
Executive Vice President EMEAI - Global Head for Geolocation and Enterprise Services
+31 6 51 13 90 39
frank.koopman@actility.com

SEQUANS
Kimberly Tassin
Director, Marketing Communications-
425.736.0569
kimberly@sequans.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye